1.Assessment of buccal bone thickness of aesthetic maxillary region: a cone-beam computed tomography study.
Ramon FUENTES ; Tania FLORES ; Pablo NAVARRO ; Carlos SALAMANCA ; Victor BELTRAN ; Eduardo BORIE
Journal of Periodontal & Implant Science 2015;45(5):162-168
PURPOSE: The aim of this study was to analyze the anatomical dimensions of the buccal bone walls of the aesthetic maxillary region for immediate implant placement, based upon cone-beam computed tomography (CBCT) scans in a sample of adult patients. METHODS: Two calibrated examiners analyzed a sample of 50 CBCT scans, performing morphometric analyses of both incisors and canines on the left and right sides. Subsequently, in the sagittal view, a line was traced through the major axis of the selected tooth. Then, a second line (E) was traced from the buccal to the palatal wall at the level of the observed bone ridges. The heights of the buccal and palatal bone ridges were determined at the major axis of the tooth. The buccal bone thickness was measured across five lines. The first was at the level of line E. The second was at the most apical point of the tooth, and the other three lines were equidistant between the apical and the cervical lines, and parallel to them. Statistical analysis was performed with a significance level of P< or =0.05 for the bone thickness means and standard deviations per tooth and patient for the five lines at varying depths. RESULTS: The means of the buccal wall thicknesses in the central incisors, lateral incisors and canines were 1.14+/-0.65 mm, 0.95+/-0.67 mm and 1.15+/-0.68 mm, respectively. Additionally, only on the left side were significant differences in some measurements of buccal bone thickness observed according to age and gender. However, age and gender did not show significant differences in heights between the palatal and buccal plates. In a few cases, the buccal wall had a greater height than the palatal wall. CONCLUSIONS: Less than 10% of sites showed more than a 2-mm thickness of the buccal bone wall, with the exception of the central incisor region, wherein 14.4% of cases were > or =2 mm.
Adult
;
Axis, Cervical Vertebra
;
Cone-Beam Computed Tomography*
;
Esthetics, Dental
;
Humans
;
Incisor
;
Tooth
2.Are Tattoos an Indicator of Severity of Non-Suicidal Self-Injury Behavior in Adolescents?
Marco Antonio SOLÍS-BRAVO ; Yassel FLORES-RODRÍGUEZ ; Liliana Guadalupe TAPIA-GUILLEN ; Aymara GATICA-HERNÁNDEZ ; Miriam GUZMÁN-RESÉNDIZ ; Luis Alberto SALINAS-TORRES ; Tania Lucila VARGAS-RIZO ; Lilia ALBORES-GALLO
Psychiatry Investigation 2019;16(7):504-512
OBJECTIVE: To compare adolescents with non-suicidal self-injury behavior and tattoos [NSSI (T+)] with another group with non-suicidal self-injury behavior without tattoos [NSSI (T−)]. METHODS: Adolescents (n=438) 42.6% males from the community (M=12.3, SD=1.3), completed the Self-Injury Schedule. RESULTS: The lifetime prevalence of tattoos performed with the purpose to feel pain was 1.8%. Compared to the NSSI (T−) group, the NSSI (T+) group was significantly more likely to meet the DSM-5 frequency criteria of 5 self-injury events in 1 year, practice more than one method of self-injury, and topography, more suicidal intentionality, more negative thoughts and affective emotions before, during, and after self-injury and more academic and social dysfunction. CONCLUSION: Adolescents from the community who practice tattooing to feel pain, show a distinct phenotype of NSSI. Health professionals and pediatricians should assess tattooing characteristics such as intention (to feel pain), frequency, and presence of non-suicidal self-injury behavior and suicide intentionality.
Adolescent
;
Appointments and Schedules
;
Health Occupations
;
Humans
;
Intention
;
Male
;
Methods
;
Phenotype
;
Prevalence
;
Suicide
;
Tattooing
3.Doxazosin Treatment Attenuates Carbon Tetrachloride-Induced Liver Fibrosis in Hamsters through a Decrease in Transforming Growth Factor beta Secretion.
Martin Humberto MUNOZ-ORTEGA ; Raul Wiliberto LLAMAS-RAMIREZ ; Norma Isabel ROMERO-DELGADILLO ; Tania Guadalupe ELIAS-FLORES ; Edgar DE JESUS TAVARES-RODRIGUEZ ; Maria DEL ROSARIO CAMPOS-ESPARZA ; Daniel CERVANTES-GARCIA ; Luis MUNOZ-FERNANDEZ ; Martin GERARDO-RODRIGUEZ ; Javier VENTURA-JUAREZ
Gut and Liver 2016;10(1):101-108
BACKGROUND/AIMS: The development of therapeutic strategies for the treatment of cirrhosis has become an important focus for basic and clinical researchers. Adrenergic receptor antagonists have been evaluated as antifibrotic drugs in rodent models of carbon tetrachloride (CCl4)-induced cirrhosis. The aim of the present study was to evaluate the effects of carvedilol and doxazosin on fibrosis/cirrhosis in a hamster animal model. METHODS: Cirrhotic-induced hamsters were treated by daily administration of carvedilol and doxazosin for 6 weeks. Hepatic function and histological evaluation were conducted by measuring biochemical markers, including total bilirubin, aspartate aminotransferase, alanine aminotransferase and albumin, and liver tissue slices. Additionally, transforming growth factor beta (TGF-beta) immunohistochemistry was analyzed. RESULTS: Biochemical markers revealed that hepatic function was restored after treatment with doxazosin and carvedilol. Histological evaluation showed a decrease in collagen type I deposits and TGF-beta-secreting cells. CONCLUSIONS: Taken together, these results suggest that the decrease in collagen type I following treatment with doxazosin or carvedilol is achieved by decreasing the profibrotic activities of TGF-beta via the blockage of alpha1- and beta-adrenergic receptor. Consequently, a diminution of fibrotic tissue in the CCl4-induced model of cirrhosis is achieved.
Adrenergic alpha-1 Receptor Antagonists/*pharmacology
;
Alanine Transaminase/blood
;
Animals
;
Aspartate Aminotransferases/blood
;
Bilirubin/blood
;
Carbazoles/*pharmacology
;
Carbon Tetrachloride
;
Collagen Type I/drug effects/metabolism
;
Cricetinae
;
Doxazosin/*pharmacology
;
Liver/metabolism/pathology
;
Liver Cirrhosis/blood/chemically induced/*drug therapy
;
Liver Function Tests
;
Propanolamines/*pharmacology
;
Serum Albumin/analysis
;
Transforming Growth Factor beta/blood/*drug effects